People around the globe have suffered serious adverse reactions resulting from COVID vaccines, especially from the Pfizer shot.
After receiving Pfizer`s Respiratory Syncytial Virus (RSV) shot during a clinical trial, two older individuals contracted Guillain-Barré syndrome.
This was enough for the FDA to flag the disease as “an important potential risk” from the RSV shot.
Warm Up Your Bedroom With Cozy Comforters And Covers From MyPillow (Now Up To 70% Off) While most people recover from Guillain-Barre syndrome, some severe cases can be fatal.
The Gateway Pundit previously reported on individuals contracting the disorder after receiving the COVID vaccine.
The Epoch Times reported: The Food and Drug Administration (FDA) stated that two older adults who received Pfizer`s respiratory syncytial virus (RSV) vaccine during a clinical trial were subsequently diagnosed with the rare neurological disorder Guillain-Barré syndrome.
24 ahead of this week`s meeting of the Vaccines and Related Biological Products Advisory Committee flagged the two cases of the disorder and stated that Pfizer`s vaccine poses a potential risk.
” Two people in their 60s who received the RSV vaccine were diagnosed with Guillain-Barré syndrome in a phase 3 trial, which involved 20,000 recipients of the vaccine.
The briefing documents show that the FDA asked Pfizer to conduct a safety study if the RSV vaccine is approved in the spring.
No safety concerns were identified by Pfizer during the trial and the company stated that it would carry out a safety study on its RSV vaccine if approved.
The FDA`s briefing documents state that Pfizer`s RSV vaccine was 85.
One should also count on more complications arising from “unknown” causes should the FDA approve Pfizer`s RSV shot.
No comments:
Post a Comment